DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Denis Chem Lab Ltd (DENISCHEM) share price today?

Denis Chem Lab Ltd (DENISCHEM) is trading at ₹70.84 on the BSE, up 1.20% on the day. Source: DocStoX.

What is the PE ratio of Denis Chem Lab Ltd?

Denis Chem Lab Ltd has a price-to-earnings (PE) ratio of 12.2 in the Healthcare sector.

What is the market capitalisation of Denis Chem Lab Ltd?

Denis Chem Lab Ltd has a market capitalisation of approximately ₹102 crore.

Denis Chem Lab Ltd

DENISCHEM·BSE·Healthcare

₹70.84▲ +0.84 (+1.20%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹70.31

₹73.85

52W₹56

₹10331%

Open

₹72.39

High

₹73.85

Low

₹70.31

Prev Close

₹70.00

Volume

72.4K

VWAP

₹72.23

Snapshot

Key fundamentals

Market Cap

₹102 Cr

P/E Ratio

12.17Cheap

P/B Ratio

1.06

EPS

₹5.82

Book Value

₹65.99

ROE

9.49%Average

ROCE

14.00%Decent

Dividend Yield

2.14%

Debt / Equity

0.04Low

Face Value

₹10.00

52W High

₹103.00

52W Low

₹56.10

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹74

▲ 4.2%upside

Trading at ₹71 — 4% below our estimate

BearFair valueBull

₹63₹74₹109

/100

Business quality — Watch the fundamentals

Growth 50Profitability 19Efficiency 30Valuation 96

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Reasonably priced at 12× earnings

How we got there

Fair value methods

Residual income

9% ROE fading to 12% over ~3 yrs, on ₹66 book

₹64

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹109

Analyst target

No analyst coverage

—

Blended fair value₹74

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Reasonably priced at 12× earnings

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

12.2Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

9.5%Average

Above 15% is considered healthy for Indian equities

ROCE

14.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.04Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹102 Cr

P/B

1.06

EPS

₹5.82

Div Yield

2.14%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 12.2×

Growth

Slow

+4% rev CAGR

Profitability

Modest

9.5% ROE

Financial health

Rock solid

D/E 0.04

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹52.32L Cr

Trades184

VWAP₹72.23

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+4.1%

+10.8%

10Y

+6.4%

Profit

+0.2%

+32.1%

10Y

—

EPS

+12.4%

+37.6%

10Y

—

Profile

Pros

Company is almost debt free.
Stock is trading at 1.06 times its book value
Company has been maintaining a healthy dividend payout of 32.7%

Watch-outs

Cons

The company has delivered a poor sales growth of 10.8% over past five years.
Promoter holding is low: 39.0%
Company has a low return on equity of 11.2% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

39%

Promoter

Promoters

39.0%0.00

Public

28.9%-0.01

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

32.1%

Total shareholders

6,927-175 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter38.98%

FII0.01%

Public28.93%

Others32.08%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1982, Denis Chem Lab Ltd does manufacturing of Pharmaceuticals Transfusion Solution in Bottles[1]